Literature DB >> 20934499

Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution.

Jie Shen1, Yanping Deng, Xuefeng Jin, Qineng Ping, Zhigui Su, Lejun Li.   

Abstract

Ophthalmic drug delivery with long pre-corneal retention time and high penetration into aqueous humor and intraocular tissues is the key-limiting factor for the treatment of ocular diseases and disorders. Within this study, the conjugate of cysteine-polyethylene glycol monostearate (Cys-PEG-SA) was synthesized and was used to compose the thiolated nanostructured lipid carrier (Cys-NLC) as a potential nanocarrier for the topical ocular administration of cyclosporine A (CyA). The rapid cross-linking process of Cys-PEG-SA in vitro was found in simulated physiological environment. The in vitro CyA release from Cys-NLC was slower than that of non-thiolated nanostructured lipid carriers (NLC) due to the cross-linking of thiomers on the surface of nanocarriers. After topical ocular administration in rabbits, the in vivo ocular distribution of CyA was investigated in comparison of Cys-NLC with non-thiolated NLCs and oil solution. The results showed that CyA concentration in systemic blood was very low and close to the detection limit. The area-under-the-curve (AUC(0-24h)) and mean retention time (MRT(0-24h)) of Cys-NLC group in aqueous humor, tear and eye tissues were significantly higher than that of oil solution, non-thiolated NLCs (p<0.05). These results demonstrated that the thiolated NLC could deliver high level of CyA into intraocular tissues due to its bioadhesive property and sustained release characteristics.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20934499     DOI: 10.1016/j.ijpharm.2010.10.008

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

Review 1.  Nanoparticles for drug delivery to the anterior segment of the eye.

Authors:  Dileep R Janagam; Linfeng Wu; Tao L Lowe
Journal:  Adv Drug Deliv Rev       Date:  2017-04-06       Impact factor: 15.470

2.  Therapeutic Benefits from Nanoparticles: The Potential Significance of Nanoscience in Retinal Degenerative Diseases.

Authors:  Raju V S Rajala
Journal:  J Mol Biol Ther       Date:  2019

3.  Ocular Application of Dirithromycin Incorporated Polymeric Nanoparticles: an In Vitro Evaluation.

Authors:  Ebru Başaran
Journal:  Turk J Pharm Sci       Date:  2017-08-15

Review 4.  An overview on dry eye treatment: approaches for cyclosporin a delivery.

Authors:  Burçin Yavuz; Sibel Bozdağ Pehlivan; Nurşen Unlü
Journal:  ScientificWorldJournal       Date:  2012-04-24

Review 5.  Thiolated Nanoparticles for Biomedical Applications: Mimicking the Workhorses of Our Body.

Authors:  Nathalie Hock; Giuseppe Francesco Racaniello; Sam Aspinall; Nunzio Denora; Vitaliy V Khutoryanskiy; Andreas Bernkop-Schnürch
Journal:  Adv Sci (Weinh)       Date:  2021-11-12       Impact factor: 16.806

6.  Preparation and in vitro and in vivo characterization of cyclosporin A-loaded, PEGylated chitosan-modified, lipid-based nanoparticles.

Authors:  Ling Zhang; Zhi-Liang Zhao; Xiao-Hong Wei; Jin-Hua Liu
Journal:  Int J Nanomedicine       Date:  2013-02-05

Review 7.  Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations.

Authors:  Rubén Varela-Fernández; Victoria Díaz-Tomé; Andrea Luaces-Rodríguez; Andrea Conde-Penedo; Xurxo García-Otero; Asteria Luzardo-Álvarez; Anxo Fernández-Ferreiro; Francisco J Otero-Espinar
Journal:  Pharmaceutics       Date:  2020-03-16       Impact factor: 6.321

Review 8.  Lipid Nanoparticles as a Promising Drug Delivery Carrier for Topical Ocular Therapy-An Overview on Recent Advances.

Authors:  Shery Jacob; Anroop B Nair; Jigar Shah; Sumeet Gupta; Sai H S Boddu; Nagaraja Sreeharsha; Alex Joseph; Pottathil Shinu; Mohamed A Morsy
Journal:  Pharmaceutics       Date:  2022-02-27       Impact factor: 6.321

9.  Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development, in-vitro and in vivo study.

Authors:  Qing Luo; Jingjing Yang; Haohang Xu; Jieran Shi; Zhen Liang; Rui Zhang; Ping Lu; Guojuan Pu; Ningmin Zhao; Junjie Zhang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.